Alcon has announced its latest dry eye innovation, the Systane® iLux2® Meibomian Gland Dysfunction (MGD) Thermal Pulsation System. With new imaging technology to capture infrared photos and HD video of the meibomian glands, this all-in-one handheld device allows patients to see the need for treatment and visualize their procedure, and experience results in as little as one week.
“Alcon is dedicated to the advancement of medical device technology and providing Eye Care Professionals (ECPs) with the tools needed to effectively treat their patients,” said Fred Ellis, Vice President, U.S. Pharmaceutical and Dry Eye, Alcon. “With the Systane iLux2 MGD Thermal Pulsation System, ECPs will be able to further patient trust and confidence because seeing is believing.”
The Systane iLux2 MGD Thermal Pulsation System expands Alcon’s current dry eye treatment offerings and allows practitioners to tailor MGD treatment to the needs of each of their patients in eight to twelve minutes.
- The device’s imaging technology allows patients to view both their meibomian glands and treatment through infrared imaging and HD video of the procedure.
- ECPs can customize heat and compression across each easy-to-visualize treatment zone.
Systane iLux2 MGD Thermal Pulsation System can help Eye Care Practitioners build a strong, trusting relationship with their patients by boosting the credibility of their treatment recommendation through direct visualization of the disease and tracking the disease over time through stored meibomian gland images.
“56% of MGD patients see four or more Eye Care Practitioners in search of proper diagnosis and relief.3 This is a prevalent diagnosis in my practice, and it is essential for me to stay on top of the latest treatment options,” said Eric D. Donnenfeld, M.D., FAAO, Ophthalmic Consultants of Long Island, NY. “The new Systane iLux2 MGD Thermal Pulsation System gives me the confidence to customize treatments based on my patients’ needs and help them see, understand and value their MGD treatment.”
Full press release from Alcon.